Ultragenyx Pharmaceutical (RARE) Return on Capital Employed Growth (1y) (2015 - 2026)
Ultragenyx Pharmaceutical (RARE) Return on Capital Employed Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 2,400.00 |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn | -549.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -549.00 |
| Dec 31, 2025 | -920.00 |
| Sep 30, 2025 | -1,849.00 |
| Jun 30, 2025 | -362.00 |
| Mar 31, 2025 | 427.00 |
| Dec 31, 2024 | 693.00 |
| Sep 30, 2024 | 1,667.00 |
| Jun 30, 2024 | 1,489.00 |
| Mar 31, 2024 | 317.00 |
| Dec 31, 2023 | -335.00 |
| Sep 30, 2023 | -930.00 |
| Jun 30, 2023 | -1,941.00 |
| Mar 31, 2023 | -2,145.00 |
| Dec 31, 2022 | -2,026.00 |
| Sep 30, 2022 | -2,124.00 |
| Jun 30, 2022 | -1,807.00 |
| Mar 31, 2022 | -1,166.00 |
| Dec 31, 2021 | -394.00 |
| Mar 31, 2021 | 2,476.00 |
| Dec 31, 2020 | 2,197.00 |